Data from bisphosphonate long-term extension trials suggest that shorter term bisphosphonates may be equivalent to longer-term therapy for certain fractures types, and safety concerns have emerged about longer-term use of these agents, particularly osteonecrosis of the jaw and atypical femur fractures. Past studies had insufficient sample sizes for fracture and safety outcomes and very limited generalizability to complex patients in the community. To address these considerable osteoporosis evidence gaps, we propose a planning grant for a Pragmatic Clinical Trial (PCT) entitled the Effectiveness of DiscontinuinG bisphosphonatEs (EDGE) Study. EDGE will be a """"""""real world"""""""" effectiveness trial of an initially estimated 4100 patients randomized to continuation or discontinuation of prior alendronate therapy.
The specific aims of this planning grant are: 1) To collaborate with an advisory group of national osteoporosis, clinical trial, and community research experts established under the Medicare United with large Simple CLinical Trials Expanded network (MUSCLE) project to: a) finalize the EDGE study protocol with respect to the study population, recruitment plan, primary and secondary outcomes, data collection/analysis plan, and b) develop a manual of procedures and other study documents;2) To develop effective linkages to Medicare data and the National Death Index (NDI) allowing for long-term surveillance of participants. The primary hypothesis to be tested in the EDGE trial is that among a postmenopausal women who have received 3 years of prior alendronate therapy at the time of enrollment non-vertebral fracture risk reduction in the 3 years following enrollment is non-inferio in women randomized to stop (intervention arm) compared to women randomized to continue alendronate therapy (comparator arm). UAB and its collaborators bring substantial expertise in conducting multi-site studies with Medicare claims and other large databases. In EDGE, we will partner with primary care and specialty health care networks, including the National Research Network (NRN), which cumulatively represent close to 10,000 providers and more than 10 million patients. We will draw on a preassembled team of expert advisors and expand our developing system for easy enrollment and surveillance of study subjects in PCTs. With linked Medicare claims and pharmacy data, EDGE will fill a major need for large osteoporosis effectiveness research at a considerably lower cost.

Public Health Relevance

A planning grant will be used to finalize study design and procedures for the Effectiveness of DiscontinuinG bisphosphonatEs Study (EDGE). EDGE is an open-label, randomized, clinical trial to test the effectiveness (i.e. non-vertebral fracture risk reduction) and (pending long- term extension) safety of continuing or discontinuing alendronate therapy in postmenopausal women with osteoporosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Clinical Planning Grant Cooperative Agreement (U34)
Project #
1U34AR062891-01A1
Application #
8501962
Study Section
Special Emphasis Panel (AMSC)
Program Officer
Chen, Faye H
Project Start
2013-04-15
Project End
2015-03-31
Budget Start
2013-04-15
Budget End
2014-03-31
Support Year
1
Fiscal Year
2013
Total Cost
$329,677
Indirect Cost
$101,754
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Singh, Jasvinder A; Hossain, Alomgir; Mudano, Amy S et al. (2017) Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev 5:CD012657
Singh, Jasvinder A; Hossain, Alomgir; Tanjong Ghogomu, Elizabeth et al. (2017) Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev 3:CD012591
Singh, Jasvinder A; Ramachandran, Rekha (2016) Time trends in total ankle arthroplasty in the USA: a study of the National Inpatient Sample. Clin Rheumatol 35:239-45
Singh, Jasvinder A; Ramachandaran, Rekha (2016) Does rural residence impact total ankle arthroplasty utilization and outcomes? Clin Rheumatol 35:381-6
Singh, Jasvinder A; Ramachandran, Rekha (2015) Does hospital volume predict outcomes and complications after total shoulder arthroplasty in the US? Arthritis Care Res (Hoboken) 67:885-90
Singh, Jasvinder A; Qu, Haiyan; Yazdany, Jinoos et al. (2015) Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. J Rheumatol 42:1616-23
Shahid, Hania; Singh, Jasvinder A (2015) Investigational drugs for hyperuricemia. Expert Opin Investig Drugs 24:1013-30
Singh, Jasvinder A; Inacio, Maria C S; Namba, Robert S et al. (2015) Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken) 67:718-24
Singh, Jasvinder A; Bharat, Aseem; Edwards, N Lawrence (2015) An internet survey of common treatments used by patients with gout including cherry extract and juice and other dietary supplements. J Clin Rheumatol 21:225-6
Burton, Mary Jane; Curtis, Jeffrey R; Yang, Shuo et al. (2015) Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Res Ther 17:136

Showing the most recent 10 out of 21 publications